AUTO-1NG is a gene-modified cell therapy commercialized by Autolus Therapeutics, with a leading Phase II program in Burkitt Lymphoma. According to Globaldata, it is involved in 2 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of AUTO-1NG’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for AUTO-1NG is expected to reach an annual total of $95 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
AUTO-1NG is under development for the treatment of relapsed or refractory acute lymphoblastic leukemia, Burkitt lymphoma, acute myelocytic leukemia (AML, acute myeloblastic leukemia), chronic lymphocytic leukemia (CLL), chronic myelocytic leukemia (CML, chronic myeloid leukemia), hairy cell leukemia, Hodgkin lymphoma (B-cell Hodgkin lymphoma) in pediatrics. It is a chimeric antigen receptor (CAR) T cell therapy comprising of CD19 CAR of AUTO-1 and a novel CD22 CAR. The drug candidate acts by targeting CD19 and CD22 expressing cancer cells.
Autolus Therapeutics Overview
Autolus Therapeutics (Autolus), formerly Autolus Therapeutics is a clinical-stage biopharmaceutical company. It offers programmed T cell therapies for the treatment of hematological cancers and solid tumors. Autolus pipeline products includes Obe-cel, AUTO1/22, AUTO5, AUTO6NG, AUTO7 and AUTO8. It has also developed proprietary viral vector and semi-automated cell manufacturing processes, which are used in clinical-stage programs. The company collaborates with leading academic institutions and industry partners to develop and deliver programmed T cell product candidates for cancer patients. Autolus is headquartered in London, Greater London, the UK.
The company reported revenues of (US Dollars) US$2.3 million for the fiscal year ended December 2021 (FY2021), an increase of 35.9% over FY2020. The operating loss of the company was US$165 million in FY2021, compared to an operating loss of US$168.2 million in FY2020. The net loss of the company was US$142.1 million in FY2021, compared to a net loss of US$142.1 million in FY2020.
For a complete picture of AUTO-1NG’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.